心房颤动患者卒中前抗栓治疗与急性缺血性卒中严重程度及院内结局的关联
该回顾性观察研究纳入2012年10月至2015年3月期间1622家参与Get With the Guidelines-Stroke项目的医院收治的94 474例有房颤病史的急性缺血性卒中患者。卒中前7.6%接受治疗性华法林(INR≥2)、8.8%接受NOACs,83.6%未接受治疗性抗凝,其中13.5%为华法林抗凝不足(INR<2)、39.9%仅接受抗血小板治疗、30.3%未接受任何抗栓治疗。未调整分析显示,治疗性华法林和NOACs组中重度卒中及院内死亡率低于无抗栓、仅抗血小板及华法林抗凝不足组。调整混杂因素后,与无抗栓治疗相比,治疗性华法林、NOACs或抗血小板治疗与中重度卒中风险降低(aOR分别为0.56、0.65、0.88)及院内死亡风险降低(aOR分别为0.75、0.79、0.83)相关。
要点
- 94 474例房颤合并急性缺血性卒中患者中,83.6%卒中前未接受治疗性抗凝,30.3%未接受任何抗栓治疗。
- 91 155例卒中前CHA2DS2-VASc评分≥2的高危患者中,83.5%卒中前未接受治疗性华法林或NOACs。
- 未调整中重度卒中率:治疗性华法林15.8%、NOACs 17.5%,低于无抗栓27.1%、仅抗血小板24.8%、华法林抗凝不足25.8%。
- 调整后与无抗栓治疗相比,治疗性华法林、NOACs、抗血小板治疗的中重度卒中aOR分别为0.56、0.65、0.88,院内死亡aOR分别为0.75、0.79、0.83。
- 卒中前治疗性抗凝与较低的卒中严重程度和院内死亡风险相关,但研究为回顾性观察设计。
适用人群与场景
- 有房颤病史的急性缺血性卒中患者,纳入94 474例,平均年龄79.9岁(SD 11.0),57.0%为女性。
- 来自2012年10月至2015年3月期间1622家参与Get With the Guidelines-Stroke项目的医院。
诊断标准与关键阈值
- 卒中严重程度采用美国国立卫生研究院卒中量表(NIHSS,范围0-42,评分越高卒中越严重,≥16分表示中重度卒中)。
- 治疗性华法林定义为国际标准化比值(INR)≥2;华法林抗凝不足定义为INR<2。
- 卒中前CHAD2DS2-VASc评分≥2定义为高危患者。
研究设计与关键结果
- 研究类型:回顾性观察研究,样本量94 474例,1622家医院,人群为有房颤病史的急性缺血性卒中患者。
- 暴露:卒中前抗栓治疗,包括治疗性华法林(INR≥2,7176例,7.6%)、NOACs(8290例,8.8%)、华法林抗凝不足(INR<2,12 751例,13.5%)、仅抗血小板治疗(37 674例,39.9%)、无任何抗栓治疗(28 583例,30.3%)。
- 主要终点:未调整中重度卒中率治疗性华法林15.8%(95%CI 14.8%-16.7%)、NOACs 17.5%(95%CI 16.6%-18.4%)、无抗栓治疗27.1%(95%CI 26.6%-27.7%)、仅抗血小板24.8%(95%CI 24.3%-25.3%)、华法林抗凝不足25.8%(95%CI 25.0%-26.6%)。
- 次要终点:未调整院内死亡率治疗性华法林6.4%(95%CI 5.8%-7.0%)、NOACs 6.3%(95%CI 5.7%-6.8%)、无抗栓治疗9.3%(95%CI 8.9%-9.6%)、仅抗血小板8.1%(95%CI 7.8%-8.3%)、华法林抗凝不足8.8%(95%CI 8.3%-9.3%)。
- 调整后与无抗栓治疗相比,中重度卒中aOR:治疗性华法林0.56(95%CI 0.51-0.60)、NOACs 0.65(95%CI 0.61-0.71)、抗血小板0.88(95%CI 0.84-0.92)。
- 调整后与无抗栓治疗相比,院内死亡aOR:治疗性华法林0.75(95%CI 0.67-0.85)、NOACs 0.79(95%CI 0.72-0.88)、抗血小板0.83(95%CI 0.78-0.88)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在有房颤病史的急性缺血性卒中患者中,卒中前治疗性抗凝(华法林INR≥2或NOACs)与较低的中重度卒中及院内死亡风险相关;本研究为回顾性观察设计,不能确立因果关系。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Antithrombotic therapies are known to prevent stroke for patients with atrial fibrillation (AF) but are often underused in community practice.
OBJECTIVES: To examine the prevalence of patients with acute ischemic stroke with known history of AF who were not receiving guideline-recommended antithrombotic treatment before stroke and to determine the association of preceding antithrombotic therapy with stroke severity and in-hospital outcomes.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective observational study of 94 474 patients with acute ischemic stroke and known history of AF admitted from October 2012 through March 2015 to 1622 hospitals participating in the Get With the Guidelines-Stroke program.
EXPOSURES: Antithrombotic therapy before stroke.
MAIN OUTCOMES AND MEASURES: Stroke severity as measured by the National Institutes of Health Stroke Scale (NIHSS; range of 0-42, with a higher score indicating greater stroke severity and a score ≥16 indicating moderate or severe stroke), and in-hospital mortality.
RESULTS: Of 94 474 patients (mean [SD] age, 79.9 [11.0] years; 57.0% women), 7176 (7.6%) were receiving therapeutic warfarin (international normalized ratio [INR] ≥2) and 8290 (8.8%) were receiving non-vitamin K antagonist oral anticoagulants (NOACs) preceding the stroke. A total of 79 008 patients (83.6%) were not receiving therapeutic anticoagulation; 12 751 (13.5%) had subtherapeutic warfarin anticoagulation (INR <2) at the time of stroke, 37 674 (39.9%) were receiving antiplatelet therapy only, and 28 583 (30.3%) were not receiving any antithrombotic treatment. Among 91 155 high-risk patients (prestroke CHA2DS2-VASc score ≥2), 76 071 (83.5%) were not receiving therapeutic warfarin or NOACs before stroke. The unadjusted rates of moderate or severe stroke were lower among patients receiving therapeutic warfarin (15.8% [95% CI, 14.8%-16.7%]) and NOACs (17.5% [95% CI, 16.6%-18.4%]) than among those receiving no antithrombotic therapy (27.1% [95% CI, 26.6%-27.7%]), antiplatelet therapy only (24.8% [95% CI, 24.3%-25.3%]), or subtherapeutic warfarin (25.8% [95% CI, 25.0%-26.6%]); unadjusted rates of in-hospital mortality also were lower for those receiving therapeutic warfarin (6.4% [95% CI, 5.8%-7.0%]) and NOACs (6.3% [95% CI, 5.7%-6.8%]) compared with those receiving no antithrombotic therapy (9.3% [95% CI, 8.9%-9.6%]), antiplatelet therapy only (8.1% [95% CI, 7.8%-8.3%]), or subtherapeutic warfarin (8.8% [95% CI, 8.3%-9.3%]). After adjusting for potential confounders, compared with no antithrombotic treatment, preceding use of therapeutic warfarin, NOACs, or antiplatelet therapy was associated with lower odds of moderate or severe stroke (adjusted odds ratio [95% CI], 0.56 [0.51-0.60], 0.65 [0.61-0.71], and 0.88 [0.84-0.92], respectively) and in-hospital mortality (adjusted odds ratio [95% CI], 0.75 [0.67-0.85], 0.79 [0.72-0.88], and 0.83 [0.78-0.88], respectively).
CONCLUSIONS AND RELEVANCE: Among patients with atrial fibrillation who had experienced an acute ischemic stroke, inadequate therapeutic anticoagulation preceding the stroke was prevalent. Therapeutic anticoagulation was associated with lower odds of moderate or severe stroke and lower odds of in-hospital mortality.
参考来源
- Xian Y, O'Brien EC, Liang L, et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017. PMID: 28291892. doi:10.1001/jama.2017.1371
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。